Connor, Clark & Lunn Investment Management (CC&L)
RETA

Connor, Clark & Lunn Investment Management (CC&L)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,842
Closed -$550K – 1266
2021
Q4 		$550K Buy
20,842
+12,047
+137% +$932K ﹤0.01% 782
2021
Q3 		$885K Buy
+8,795
New +$1.03M ﹤0.01% 667

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RETA Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 20,842 shares — an estimated $550K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RETA in Q3 2021 and held it in 2 quarters. The position peaked at $885K in Q3 2021. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 20,842 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $550K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $885K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.